Akèy › Kansè Poumon ki pa ti selil › Illinois › Peoria
Etid klinik pou Kansè Poumon ki pa ti selil nan Peoria, IL
21 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Peoria (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Illinois CancerCare-Peoria, Peoria
- Illinois CancerCare-Pekin, Pekin · 9 mi lwen
- Illinois CancerCare-Canton, Canton · 25 mi lwen
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Ap rekriteFaz 2
- Illinois CancerCare-Peoria, Peoria
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria
- OSF Saint Francis Medical Center, Peoria
- ak 3 plis
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Ap rekriteFaz 2/3
- OSF Saint Francis Medical Center, Peoria
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Ap rekriteFaz 3
- Illinois Cancer Care ( Site 7000), Peoria
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Ap rekriteFaz 3
- Illinois CancerCare-Peoria, Peoria
- Illinois CancerCare-Pekin, Pekin · 9 mi lwen
- Illinois CancerCare-Canton, Canton · 25 mi lwen
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Ap rekriteFaz 3
- Illinois Cancer Care, Peoria
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Illinois Cancer Care, Peoria
- Illinois CancerCare- Pekin, Pekin · 9 mi lwen
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Illinois CancerCare, P.C., Peoria
- Illinois CancerCare-Pekin, Pekin · 9 mi lwen
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Illinois CancerCare, Peoria
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- OSF Saint Francis Medical Center, Peoria
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- Illinois CancerCare-Peoria, Peoria
- Methodist Medical Center of Illinois, Peoria
- Illinois CancerCare-Pekin, Pekin · 9 mi lwen
- ak 1 plis
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1
- OSF Health Care, Peoria
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- OSF Saint Francis Medical Center, Peoria
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- OSF Healthcare System; Saint Francis Medical Center, Peoria
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- St. Francis Medical Center (OSF Healthcare), Peoria
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Illinois CancerCare-Peoria, Peoria
- Illinois CancerCare-Pekin, Pekin · 9 mi lwen
- Illinois CancerCare-Canton, Canton · 25 mi lwen
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Ap rekriteFaz 1
- OSF Healthcare Cancer Institute, Peoria
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Illinois CancerCare-Peoria, Peoria
- Illinois CancerCare-Pekin, Pekin · 9 mi lwen
- Illinois CancerCare-Canton, Canton · 25 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Illinois CancerCare-Peoria, Peoria
- Illinois CancerCare-Pekin, Pekin · 9 mi lwen
- Illinois CancerCare-Canton, Canton · 25 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Illinois CancerCare-Peoria, Peoria
- Illinois CancerCare-Pekin, Pekin · 9 mi lwen
- Illinois CancerCare-Canton, Canton · 25 mi lwen
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Illinois CancerCare-Peoria, Peoria
- Illinois CancerCare-Pekin, Pekin · 9 mi lwen
- Illinois CancerCare-Canton, Canton · 25 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
Lòt etid nan Peoria
- Kansè poumon12 etid
- Kansè kolorektal12 etid
- Kansè pwostat9 etid
- Ensifizyans kadyak8 etid
- Kansè nan tete8 etid
- Kansè ovè7 etid
- Karsinòm selil skuamèz tèt ak kou7 etid
- Kansè Metastatik7 etid
- Kansè pankreyas7 etid
- Kansè (tout kalite)7 etid
- Melanom6 etid
- Kansè Endomèt6 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.